Gossamer Bio, Inc. (GOSS)
Stock Price Chart
Key Info
| Market Cap | 873.28M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -201.77M |
| Shares Out | 75.79M |
| EPS (ttm) | -3.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Jul 2, 2020 |
| Last Price | $13.16 |
| Previous Close | $12.82 |
| Change ($) | 0.34 |
| Change (%) | 2.65% |
| Day's Open | 13.00 |
| Day's Range | 12.87 - 13.30 |
| Day's Volume | 485,566 |
| 52-Week Range | 7.52 - 27.15 |
More Stats
| Market Cap | 873.28M |
| Enterprise Value | 563.76M |
| Earnings Date (est) | Aug 6, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 75.79M |
| Float | 39.18M |
| EPS (basic) | -3.31 |
| EPS (diluted) | -3.30 |
| FCF / Share | -2.79 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 5.69M |
| Short Ratio | 5.35 |
| Short % of Float | 9.56% |
| Beta | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | n/a |
| PB Ratio | 3.16 |
| Revenue | n/a |
| Operating Income | -207.09M |
| Net Income | -201.77M |
| Free Cash Flow | -172.49M |
| Net Cash | 309.51M |
| Net Cash / Share | 4.66 |
| Gross Margin | n/a |
| Operating Margin | n/a |
| Profit Margin | n/a |
| FCF Margin | n/a |
| ROA | -28.41% |
| ROE | -51.29% |
| ROIC | -63.40% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Operating Income | -186 | -149 | -6.65 | -0.08 |
| Net Income | -180 | -147 | -6.77 | -0.08 |
| Shares Outstanding | 54.74 | 6.50 | 9.16 | 9.16 |
| Earnings Per Share | -3.29 | -22.59 | -0.74 | -0.01 |
| Operating Cash Flow | -145 | -51.04 | -5.75 | 0.02 |
| Capital Expenditures | -2.97 | -3.49 | - | - |
| Free Cash Flow | -148 | -54.53 | -5.75 | 0.02 |
| Cash & Equivalents | 402 | 229 | 0.32 | 0.06 |
| Total Debt | 37.20 | - | 6.04 | 0.04 |
| Net Cash / Debt | 365 | 229 | -5.73 | 0.02 |
| Assets | 427 | 239 | 0.45 | 0.06 |
| Liabilities | 74.12 | 21.12 | 7.31 | 0.18 |
| Book Value | 352 | -120 | -6.86 | -0.12 |
Company Profile
Company Details
| Full Name | Gossamer Bio, Inc. |
| Country | United States |
| Employees | 171 |
| CEO | Sheila Gujrathi |
Stock Information
| Ticker Symbol | GOSS |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: GOSS |
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis both with and without nasal polyps; and in translational Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, selective platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a novel, gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and certain backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.